research on fibromyalgia lagged behind other diseases, but a 2002 study was a turning point. The study identified abnormalities in the brain’s pain processing mechanisms in fibromyalgia patients, providing the objective evidence needed to classify it as a real medical condition. This discovery spurred a decade of research, culminating in FDA approval for three drugs that help reduce pain signals.
However, she adds:
“While these medications help manage pain, they often don’t address other debilitating symptoms such as fatigue and cognitive difficulties—commonly referred to as ‘fibrofog.’ To tackle
